UK remote
Applied AI Engineer, Beneficial Deployments (Clinical Development, Rare and Neglected Diseases)
About this role
About Anthropic Anthropic’s mission is to create reliable, interpretable, and steerable AI systems. We want AI to be safe and beneficial for our users and for society as a whole. Our team is a quickly growing group of committed researchers, engineers, policy experts, and business leaders working together to build beneficial AI systems. About Anthropic Anthropic's mission is to create reliable, interpretable, and steerable AI systems.
We want AI to be safe and beneficial for our users and for society as a whole. Our team is a quickly growing group of committed researchers, engineers, policy experts, and business leaders working together to build beneficial AI systems. About Beneficial Deployments Beneficial Deployments ensures AI reaches and benefits the communities that need it most. We partner with nonprofits, foundations, and mission-driven organizations to deploy Claude in education, global health, economic mobility, and life sciences — focusing on raising the floor for those who need it most.
About the Role We're looking for an Applied AI Engineer to join our Beneficial Deployments, Life Sciences team. This is a partner-facing role: you'll support nonprofits, research institutes, academic medical centres and public-sector funders as they use Claude to get treatments to patients with rare and neglected diseases, where there is little or no commercial incentive to fund development. The role focuses on clinical development, where we think Claude can help these partners today.
Trials in these diseases have small patient populations, investigator-led or nonprofit funding and little operational support, and they often stall on protocol quality, operational risk and site start-up. Claude can help teams design better trials and start them sooner. Much of this work is drug repurposing: testing new uses for approved, usually off-patent or generic medicines, whose known safety profiles can let a good hypothesis reach patients years sooner than a new molecule.